REGENXBIO touted data from the Phase III portion of a study that showed higher benefit that Elevidys.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ...

Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic ...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to ...

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...

The closest-ever detailed look at a key enzyme inside the virus that causes COVID-19 could lead to more effective treatment ...

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent AD ...

Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed ...

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026BASECAMP remains on track to complete enrollment in Q3 2026The Company has initiated ...

Bermuda-based Calidris Investment Partners, an insurance-focused investment manager backed by RedBird Capital Partners, has ...

Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...

Parents of children with Duchenne syndrome and their supporters spend 22nd night outside government office, continuing daily ...